[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Lin JR, Zhang WM, Wang ZC: Primary malignant bone neoplasm: a case report of dedifferentiated chondrosarcoma in the rib and review of the literature. Chin J Cancer; 2010 Nov;29(11):964-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant bone neoplasm: a case report of dedifferentiated chondrosarcoma in the rib and review of the literature.
  • Dedifferentiated chondrosarcoma (DDCS) is a rare but highly malignant primary bone neoplasm, which is resistant to radiotherapy and chemotherapy.
  • There remains uncertainly as to the best treatment of this disease and how to improve its prognosis.
  • In this paper we reported a case of DDCS and reviewed the related literatures in order to provide references to throw a light on the histogenesis, diagnosis and therapy of this disease.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Chondrosarcoma / radionuclide imaging. Hemangioendothelioma / secondary. Lung Neoplasms / secondary. Ribs
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Follow-Up Studies. Humans. Immunohistochemistry. Male. Methotrexate / administration & dosage. Multimodal Imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979697.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Mysorekar VV, Harish K, Kilara N, Subramanian M, Giridhar AG: Embryonal rhabdomyosarcoma of the chest wall: a case report and review of the literature. Indian J Pathol Microbiol; 2008 Apr-Jun;51(2):274-6
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Embryonal rhabdomyosarcoma is a soft-tissue sarcoma which has a predilection for the head and neck area, genitourinary tract and the extremities.
  • We report a rare case of embryonal rhabdomyosarcoma of the chest wall in an 8-year-old girl, presenting as a destructive tumor in the rib and clinically and radiologically mimicking Ewing's sarcoma.
  • Histopathological examination showed a small round cell tumor.
  • Immunohistochemically, the positivity for muscle markers desmin and myogenin in the tumor cells proved to be useful for making a definitive diagnosis of embryonal rhabdomyosarcoma.
  • Cytogenetic analysis revealed a high level of aneuploidy in the tumor cells, with double-minutes and additional chromosomal structural aberrations.
  • The patient is responding well to chemotherapy.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / diagnosis. Thoracic Neoplasms / diagnosis. Thoracic Wall / pathology
  • [MeSH-minor] Aneuploidy. Child. Diagnosis, Differential. Female. Humans. Sarcoma, Ewing / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603708.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 9
  •  go-up   go-down


3. Tabatabai A, Hashemi M, Ahmadinejad M, Haghdani S, Sajjadi M, Mahzouni P, Hekmatnia A: Primary chest wall lymphoma with no history of tuberculous pyothorax: diagnosis and treatment. J Thorac Cardiovasc Surg; 2008 Dec;136(6):1472-5
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chest wall lymphoma with no history of tuberculous pyothorax: diagnosis and treatment.
  • OBJECTIVE: Primary chest wall neoplasm represents only 5% of chest wall neoplasm and among them primary chest wall lymphoma is uncommon.
  • METHODS: A 28-year-old man had no history of tuberculous pyothorax or artificial pneumothorax therapy but did have a 4-month history of dyspnea, fever, chills, and night sweats.
  • Computed tomography showed mild plural effusion and erosion in the posterior segment of the left ninth rib.
  • Surgery was performed for histologic diagnosis.
  • RESULTS: With the diagnosis of large B cell lymphoma, chemotherapy was prescribed for the first patient, and the patient has been in complete remission for more than 5 months.
  • For the second patient, the left ninth rib along with the originated mass was completely resected and chemotherapy was prescribed.
  • CONCLUSION: Treatment of primary chest wall lymphoma was not clear and various treatment strategies were considered.
  • Remission of considerable duration in our patients leads us to suggest that surgery followed by adjuvant chemotherapy can provide a reasonable outcome in patients in whom the chest wall lymphoma is the only site of disease.
  • [MeSH-major] Lymphoma / diagnosis. Lymphoma / therapy. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Empyema, Tuberculous. Humans. Male. Ribs / surgery. Thoracic Wall / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19114192.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Ataergin S, Ozet A, Solchaga L, Turan M, Beyzadeoglu M, Oysul K, Arpaci F, Komurcu S, Surenkok S, Ozturk M: Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone. Med Oncol; 2009;26(3):276-86
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.
  • The outcome of Ewing's sarcoma depends on the anatomical site of the tumor.
  • We evaluated the outcome of high-risk Ewing's sarcoma patients that received long-term treatment protocol.
  • The tumor localization was pelvis (9), femur (1), tibia (1), fibula (1), maxilla (1), clavicle (1), vertebrae (5), metatarse (1), and ribs (5).
  • Neoadjuvant chemotherapy was applied between weeks 0 and 6, local therapy on week 9, and adjuvant maintenance chemotherapy between weeks 11 and 41.
  • All patients received neoadjuvant and adjuvant maintenance chemotherapy.
  • Local therapy consisted of radiotherapy (32%), surgery alone (12%), or surgery and radiotherapy (56%).
  • The median total treatment period was 10 months.
  • The most common grade III/IV toxicities observed during the treatment protocol were neutropenia (16%) and gastrointestinal toxicities (16%).
  • Our study indicated that long-term multiagent combination chemotherapy may result in better outcome in adult high-risk patients undergoing adequate surgical resection of the tumor and local radiotherapy.
  • Further randomized studies are needed to assess the efficacy of this treatment protocol in patients with adequate surgical margins.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Sarcoma, Ewing / drug therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Kaplan-Meier Estimate. Male. Mesna / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / pathology. Proportional Hazards Models. Remission Induction. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1664-74 [2213103.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1173-80 [2045857.001]
  • [Cites] Med Pediatr Oncol. 1999 Nov;33(5):444-9 [10531567.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):901-11 [8756388.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1174-83 [9506366.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):111-20 [14654912.001]
  • [Cites] Eur J Cancer. 1997 Dec;33(14):2360-7 [9616282.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2611-21 [9215832.001]
  • [Cites] Eur J Cancer. 1999 Nov;35(12):1698-704 [10674016.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1646-54 [11742482.001]
  • [Cites] Oncology. 1980;37(2):114-9 [7360479.001]
  • [Cites] J Bone Joint Surg Am. 1980 Sep;62(6):1027-30 [7000786.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):4-11 [10623687.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1562-7 [16137838.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):275-81 [9602261.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):421-8 [10430250.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):569-73 [11520091.001]
  • [Cites] Nihon Rinsho. 2003 Jun;61(6):937-42 [12806939.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1477-86 [2924256.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):367-73 [15948159.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):276-83 [10472562.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2818-25 [2025847.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1818-29 [11251014.001]
  • [Cites] J Chemother. 1997 Oct;9(5):352-63 [9373791.001]
  • [Cites] J Bone Joint Surg Am. 1993 Oct;75(10):1457-65 [8408134.001]
  • [Cites] Am J Clin Oncol. 1988 Dec;11(6):614-7 [3189226.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):533-7 [14623923.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3108-14 [10963639.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Feb;25(2):118-24 [12571462.001]
  • [Cites] Cancer. 1988 Jan 1;61(1):23-32 [3334950.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):766-72 [16626886.001]
  • [Cites] Cancer. 1981 May 1;47(9):2204-13 [7226113.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):767-75 [17238190.001]
  • [Cites] Clin Orthop Relat Res. 2000 Apr;(373):193-201 [10810477.001]
  • [Cites] Jpn J Clin Oncol. 2004 Nov;34(11):667-72 [15613556.001]
  • [Cites] J Bone Joint Surg Br. 2003 Jan;85(1):107-14 [12585587.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jun;119(6):1154-61 [10838532.001]
  • [Cites] Cancer. 1967 Oct;20(10):1602-6 [6058169.001]
  • [Cites] Eur J Cancer. 2000 May;36(7):875-80 [10785592.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):168-77 [12504050.001]
  • [Cites] Acta Oncol. 2006;45(4):469-75 [16760184.001]
  • [Cites] Cancer. 2000 May 1;88(9):2172-80 [10813731.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3423-30 [12972518.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):375-84 [17569105.001]
  • (PMID = 18989798.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


5. Sirvent N, Kanold J, Levy C, Dubousset J, Zucker JM, Philip T, Demaille MC, Robert A, Vannier JP, Oberlin O: Non-metastatic Ewing's sarcoma of the ribs: the French Society of Pediatric Oncology Experience. Eur J Cancer; 2002 Mar;38(4):561-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-metastatic Ewing's sarcoma of the ribs: the French Society of Pediatric Oncology Experience.
  • From 1984 to 1997, 57 consecutive patients with non-metastatic Ewing's sarcoma of the ribs were treated according to multimodal French Society of Pediatric Oncology (SFOP) protocols EW 84, EW 88 and EW 93.
  • The results of treatment were reviewed and analysed.
  • Histological response after chemotherapy was assessed in 34 patients.
  • 34 patients received radiation therapy.
  • None of the following was significant in predicting relapse: tumour size, gender, age at diagnosis, existence of pleural effusion, level of rib tumour, rib component, type of local control, surgical margin (positive or negative).
  • Response to chemotherapy was the sole significant prognostic factor (P=0.004).
  • Patients with pleural effusion had a higher percentage of relapse if they were treated without local radiation therapy.
  • Our study confirms the prognostic significance of response to initial chemotherapy.
  • Radiation therapy may be withheld in selected cases, but seems necessary in patients with pleural effusion.
  • [MeSH-major] Bone Neoplasms / therapy. Ribs. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Pleural Effusion / etiology. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11872350.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Ninomiya H, Maeda M, Matsuzaki Y, Nakamura K, Sekiya R, Onitsuka T: Giant cell tumor of the rib. Jpn J Thorac Cardiovasc Surg; 2002 May;50(5):224-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the rib.
  • In a rare case of a giant cell tumor of rib origin, a 25-year-old woman to be evaluated for an abnormal mass shadow in chest radiography was strongly positive in a tuberculin skin test, but showed no evidence of active tuberculosis.
  • Chest computed tomography showed a heterogeneous mass originating in the posterior end of the right fourth rib and containing multiple calcifications and cystic lesions.
  • Bone scintigraphy showed an abnormal marked accumulation at the tumor site.
  • A thoracoscopic examination was conducted prior to complete tumor resection, including the fourth rib and related muscles.
  • The pathological diagnosis returned was a giant cell tumor of the bone.
  • The patient did not undergo chemotherapy or radiotherapy, and remains well, and tumor-free at 6 months after surgery.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumors / surgery. Ribs
  • [MeSH-minor] Adult. Female. Humans. Thoracoscopy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12048918.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


7. Bacha D, Ayadi-Kaddour A, Fenniche S, Marghli A, Kilani T, El Mezni F: Costal chondrosarcoma. Report of five cases. Orthop Traumatol Surg Res; 2009 Apr;95(2):164-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In four cases, the tumor had spread and infiltrated the adjacent structures (soft tissues, thoracic vertebrae, mediastinum, etc.).
  • CS was diagnosed based either on wide surgical resection specimens in three patients, or on tumor biopsies in two cases.
  • Wide surgical resection which was performed in three patients was associated in one case with adjuvant radiotherapy and chemotherapy.
  • Two patients died, one after radiotherapy and chemotherapy done immediately after diagnosis as a result of the large size and invasive nature of the tumor.
  • Diagnosis remains anatomopathological.
  • Wide surgical resection is the only demonstrated curative treatment, even for high-grade CS.
  • [MeSH-major] Bone Neoplasms / pathology. Neoplasm Invasiveness / pathology. Osteochondroma / pathology. Ribs / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. Sampling Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328762.001).
  • [ISSN] 1877-0568
  • [Journal-full-title] Orthopaedics & traumatology, surgery & research : OTSR
  • [ISO-abbreviation] Orthop Traumatol Surg Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [General-notes] NLM/ Original DateCompleted: 20090724
  •  go-up   go-down


8. Gambini D, Visintin R, Locatelli E, Galassi B, Bareggi C, Runza L, Onida F, Tomirotti M: Paclitaxel-dependent prolonged and persistent complete remission four years from first recurrence of secondary breast angiosarcoma. Tumori; 2009 Nov-Dec;95(6):828-31
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among angiosarcomas, radiation-induced breast sarcomas (RIBS) represent a well-known entity generally characterized by a poor outcome, especially in patients with advanced disease.
  • Treatments with demonstrated activity against sarcomas include ifosfamide-based regimens and, more recently, taxane derivatives.
  • We report a case of a patient having a secondary breast angiosarcoma recurring early after surgery, who achieved complete remission following treatment with weekly paclitaxel.
  • After 4 years of maintenance therapy, with an interval between consecutive administrations of no longer than 3 weeks, the patient is still in complete remission.
  • A locoregional recurrence was documented twice during this period, the first as a consequence of a brief treatment interruption and the second because of a treatment delay.
  • Nonetheless, in both instances a new complete remission was rapidly achieved with the resumption of the same treatment, without evidence of any significant adverse effects.
  • We discuss the highly unusual behavior of this malignancy and the possible role of the two different mechanisms of action of paclitaxel-antiangiogenic versus cytotoxic-depending on the schedule of administration, with evidence of "false" drug-resistance.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Hemangiosarcoma / drug therapy. Mastectomy, Segmental. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Neoplasms, Second Primary / drug therapy. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210253.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Briccoli A, Rocca M, Salone M, Palmerini E, Balladelli A, Ferrari C, Di Fiore M, Bacci G: Local and systemic control of Ewing's bone sarcoma family tumors of the ribs. J Surg Oncol; 2009 Sep 1;100(3):222-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local and systemic control of Ewing's bone sarcoma family tumors of the ribs.
  • BACKGROUND: A retrospective analysis of the results and relapse pattern was evaluated in 34 patients with Ewing's family bone tumors (EFBT) treated at Rizzoli Institute with neoadjuvant chemotherapy between 1983 and 2003.
  • OBJECTIVES: The aim of the study was to evaluate treatment strategy and compare our results with those obtained in other studies.
  • METHODS: Local treatment in these patients was radiotherapy alone in 4 cases, surgery alone in 13 and surgery followed by radiotherapy in 17.
  • RESULTS: Five-year event-free survival (EFS) was 44%, no different from that observed in another 558 patients with EFBT located in other sites treated in the same period with neoadjuvant chemotherapy protocols.
  • EFS was significantly correlated to the time interval between onset symptoms and beginning of treatment and, in operated patients to histologic response to preoperative treatment.
  • CONCLUSIONS: We conclude that EFBT of the ribs, when treated with neoadjuvant chemotherapy, have an outcome similar to that of patients with EFBT located in other sites.
  • [MeSH-major] Bone Neoplasms / therapy. Neoplasm Recurrence, Local. Ribs / pathology. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Plates. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fascia Lata / transplantation. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Neoadjuvant Therapy. Neoplasm Metastasis. Radiotherapy, Adjuvant. Retrospective Studies. Surgical Mesh. Thoracotomy. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19548266.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


10. Pavlakis G, Mountzios G, Terpos E, Leivaditou A, Papadopoulos G, Papasavas P: Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:299-303
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature.
  • We present here a case of a 47-year-old woman with thoracic wall metastasis from serous-papillary ovarian carcinoma that occurred 3 years after the initial diagnosis, although the patient had received various regimens of intense platinum-based chemotherapy.
  • Special emphasis is given to the effects of alkylating agents, such as cisplatin and carboplatin, on the pattern of tumor spread.
  • We also discuss the possible mechanisms through which the biologic and metastatic behavior of this tumor is expressed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / drug therapy. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Cystadenocarcinoma, Papillary / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Epirubicin / administration & dosage. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Ribs. Sternum. Taxoids / administration & dosage. Thoracic Wall. Topotecan / administration & dosage. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515608.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7M7YKX2N15 / Topotecan; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  • [Number-of-references] 10
  •  go-up   go-down


11. Sher-Ahmed A, Buscema J, Sardi A: A case report of recurrent epithelial ovarian cancer metastatic to the sternum, diaphragm, costae, and bowel managed by aggressive secondary cytoreductive surgery without postoperative chemotherapy. Gynecol Oncol; 2002 Jul;86(1):91-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of recurrent epithelial ovarian cancer metastatic to the sternum, diaphragm, costae, and bowel managed by aggressive secondary cytoreductive surgery without postoperative chemotherapy.
  • BACKGROUND: Ovarian epithelial cancer typically presents in advanced stage and has been traditionally managed by a combination of cytoreductive surgery followed by adjuvant systematic chemotherapy.
  • The management of recurrent ovarian cancer has been individualized: surgical resection of intraabdominal and/or pelvic disease has been performed when technically feasible and usually followed with chemotherapy.
  • CASE: This case describes aggressive surgical management of recurrent ovarian cancer metastatic to the lower ribs, sternum, and diaphragm.
  • The patient had total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy followed by six cycles of adjuvant chemotherapy, consisting of cyclophospamide and carboplatinum.
  • A secondary cytoreductive surgery without further chemotherapy has been the mainstay of treatment.
  • A combination of exploratory laparotomy and en bloc resection revealed the metastatic deposits, a 5-cm mass involving the diaphragm, the lower aspect of the manubrium sternum, and four right lower ribs.
  • [MeSH-major] Bone Neoplasms / secondary. Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Aged. Diaphragm / pathology. Epithelial Cells / pathology. Female. Humans. Ribs. Sternum


12. Lin JT, Yen CC, Wang WS, Chiou TJ, Liu JH, Wu HT, Chen PM: Case report: Unusual peritoneal spreading by metastatic osteosarcoma of the tibia. Br J Radiol; 2003 May;76(905):337-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He received surgical resection and chemotherapy.
  • Despite intensive chemotherapy, the metastatic osteosarcoma of lung continued to invade the ribs and later into retroperitoneum and liver.
  • [MeSH-minor] Adolescent. Humans. Liver Neoplasms / pathology. Male. Neoplasm Invasiveness. Retroperitoneal Neoplasms / pathology. Ribs. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12763950.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Kitada M, Ozawa K, Sato K, Hayashi S, Sasajima T: Resection of a chondrosarcoma arising in the right first rib: a case report. Ann Thorac Cardiovasc Surg; 2010 Apr;16(2):118-21
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of a chondrosarcoma arising in the right first rib: a case report.
  • Primary chest wall tumors are relatively rare, and in individual cases the biological properties and onset site of the tumor must be considered before surgery, and the chest wall defect must be reconstructed.
  • The case of a patient with a chondrosarcoma arising in the right first rib who underwent resection and reconstruction is reported.
  • The patient was a 56-year-old man with a 6 × 7 cm tumor in the anterior chest wall side of the right first rib; biopsy confirmed a grade I chondrosarcoma.
  • During surgery, a safe surgical field was prepared by severing the clavicle inside the periosteum and resecting the tumor with the anterior side of the first and second ribs.
  • In the treatment of chondrosarcoma, chemotherapy and radiotherapy are less effective, and appropriate surgery is needed.
  • In the present patient it was useful to prepare a safe surgical field for resecting the first rib tumor by severing the clavicle and then reconstructing the chest wall, using the greater pectoral muscle and a polypropylene mesh.
  • [MeSH-minor] Humans. Male. Middle Aged. Ribs. Surgical Mesh. Thoracic Wall

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20930665.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Volmar KE, Sporn TA, Toloza EM, Martinez S, Dodd LG, Xie HB: Giant cell tumor of rib masquerading as thymoma: a diagnostic pitfall in needle core biopsy of the mediastinum. Arch Pathol Lab Med; 2004 Apr;128(4):452-5
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of rib masquerading as thymoma: a diagnostic pitfall in needle core biopsy of the mediastinum.
  • Giant cell tumor of bone is rarely seen in the rib, where it may present as a mediastinal mass.
  • The diagnosis of giant cell tumor of bone is generally straightforward by fine-needle aspiration or needle core biopsy, but sampling problems may lead to confusion with other neoplasms or inflammatory processes.
  • Here, we report a case of giant cell tumor of rib presenting as a mediastinal mass in a 36-year-old man.
  • Because of inadequate sampling and inaccurate clinical information, the tumor was initially mistaken for thymoma.
  • When the mass failed to respond to conventional chemotherapy, additional tissue was obtained and a giant cell tumor was diagnosed.
  • Consequently, definitive therapy was delayed.
  • [MeSH-major] Biopsy, Needle. Bone Neoplasms / diagnosis. Diagnostic Errors. Giant Cell Tumor of Bone / diagnosis. Mediastinal Neoplasms / diagnosis. Ribs / pathology. Thymoma / diagnosis. Thymus Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cell Nucleus / ultrastructure. Combined Modality Therapy. Epithelial Cells / pathology. Giant Cells / pathology. Humans. Male. Remission Induction

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15043459.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Eroğlu A, Kürkçüoğlu IC, Karaoğlanoğlu N, Alper F, Gündoğdu C: Extraskeletal Ewing sarcoma of the diaphragm presenting with hemothorax. Ann Thorac Surg; 2004 Aug;78(2):715-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ewing sarcoma is a relatively uncommon malignant bone neoplasm that usually occurs in children and young adults and involves the major long bones, pelvis, and ribs.
  • After drainage, a roentgenogram film, computed tomography, ultrasonography, and magnetic resonance image showed a giant mass on the right diaphragm.
  • Primary diaphragmatic tumor was resected totally by right posterolateral thoracotomy, and histologically, an extraskeletal Ewing sarcoma was identified.
  • The patient received adjuvant radio-chemotherapy, and there was no evidence of disease 10 months after the operation.
  • Although extremely rare, extraskeletal Ewing sarcoma should be kept in mind in the differential diagnosis of diaphragmatic soft tissue tumors.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Dyspnea / etiology. Female. Hemothorax / etiology. Humans. Ifosfamide / administration & dosage. Mesna / administration & dosage. Neoplasm Invasiveness. Organ Specificity. Radiotherapy, Adjuvant. Remission Induction. Ribs / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15276562.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


16. Petrelli F, Cabiddu M, Carpo M, Ghilardi M, Barni S: Progression of intramedullary metastasis during perioperative cessation of sunitinib. Nat Rev Urol; 2010 Nov;7(11):634-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She was enrolled in a clinical study, in which she received two cycles of neoadjuvant sunitinib therapy followed by cytoreductive nephrectomy.
  • Her primary tumor and rib metastasis showed a good response to neoadjuvant therapy; however, after surgery, the patient developed neurologic symptoms, including flaccid paraparesis with paresthesia and hypoesthesia.
  • MRI of the brain and spine revealed a leptomeningeal lesion at the T12-L1 space, which was presumed to have progressed during the 3-week treatment-free perioperative period.
  • The patient underwent radiation therapy for the intramedullary lesion 1 month later, and sunitinib therapy was subsequently reinstated.
  • DIAGNOSIS: Progression of a central nervous system metastasis linked to the interruption of neoadjuvant sunitinib therapy.
  • MANAGEMENT: Neoadjuvant sunitinib therapy followed by cytoreductive nephrectomy for the primary RCC; radiation therapy for the intramedullary lesion, followed by reinstatement of sunitinib therapy owing to a good clinical response observed in the extracranial lesions.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Indoles / administration & dosage. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Pyrroles / administration & dosage. Spinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20938435.001).
  • [ISSN] 1759-4820
  • [Journal-full-title] Nature reviews. Urology
  • [ISO-abbreviation] Nat Rev Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


17. Demura Y, Saito H, Yashiki N: [Chondrosarcoma of the rib with pleural dissemination]. Kyobu Geka; 2009 May;62(5):399-403
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chondrosarcoma of the rib with pleural dissemination].
  • Chest computed tomography (CT) showed a 10.0 x 6.6 cm mass arising from the left chest wall.
  • The diagnosis of grade II chondrosarcoma was made with CT guided percutaneous needle biopsy.
  • At operation, the irregularly-shaped tumor was arising from the 7th rib.
  • Chest wall resection and partial resection of the left lower lobe including the tumor was performed.
  • Adjuvant chemotherapy using OK-432, carboplatin and etoposide was tried as treatment for pleural dissemination.
  • Radical excision of chondrosarcoma of the rib including all pleural dissemination is difficult.
  • Multidisciplinary approach including resection of a primary tumor has potential to improve prognosis in some cell types.
  • And long term follow-up is necessary to determine effectiveness of adjuvant chemotherapy in this case.
  • [MeSH-major] Chondrosarcoma / pathology. Neoplasm Seeding. Pleural Neoplasms / secondary. Ribs. Thoracic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19425383.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Trainer S, Bergmann T, Bölükbas S, Weissbach L, Figge M, Schirren J: [The approach to tumors of the retrocrural mediastinum]. Chirurg; 2008 Jan;79(1):26-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Zugang zu retrokruralen Tumoren des Mediastinums.
  • From November 1999 to December 2005, using this approach we operated on 12 patients with residual germ cell tumors after chemotherapy.
  • [MeSH-major] Diaphragm / surgery. Mediastinal Neoplasms / surgery. Neoplasm, Residual / surgery. Neoplasms, Germ Cell and Embryonal / surgery
  • [MeSH-minor] Disease-Free Survival. Humans. Lymph Node Excision. Lymphatic Metastasis. Magnetic Resonance Imaging. Prognosis. Ribs / surgery. Teratoma / diagnosis. Teratoma / diagnostic imaging. Teratoma / secondary. Teratoma / surgery. Thoracotomy. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Thorac Cardiovasc Surg. 1992 Oct;4(4):314-9 [1457572.001]
  • [Cites] Chest Surg Clin N Am. 2002 Nov;12(4):739-48 [12471875.001]
  • [Cites] Chest Surg Clin N Am. 2002 Nov;12(4):749-68 [12471876.001]
  • [Cites] Ann Thorac Surg. 2000 Jun;69(6):1717-21 [10892913.001]
  • [Cites] Chest Surg Clin N Am. 2002 Nov;12(4):695-706 [12471872.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3713-9 [15365067.001]
  • (PMID = 18209978.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 8
  •  go-up   go-down


19. Mattioli S, D'Ovidio F, Tazzari P, Pilotti V, Daddi N, Bandini G, Piccioli M, Pileri S: Iliac crest biopsy versus rib segment resection for the detection of bone marrow isolated tumor cells from lung and esophageal cancer. Eur J Cardiothorac Surg; 2001 May;19(5):576-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iliac crest biopsy versus rib segment resection for the detection of bone marrow isolated tumor cells from lung and esophageal cancer.
  • OBJECTIVE: The presence of isolated tumor cells in the bone marrow affects the prognosis of both esophageal cancer and non-small cell lung cancer (NSCLC).
  • Therefore, preoperative assessment of isolated tumor cells may be useful to plan multimodality treatment.
  • Rib segment resection at surgery provides adequate amounts of bone marrow for the detection of isolated tumor cells while bone marrow aspirate from the iliac crest does not.
  • The iliac crest biopsy according to the Jamshidi technique procures a core of tissue apt for histology and not simply for cytology.
  • The aim of this study was to compare the accuracy of iliac crest biopsy versus rib segment resection in the diagnosis of isolated tumor cells in order to obtain a useful preoperative approach.
  • None had chemotherapy prior to evaluation.
  • Bone marrow was obtained preoperatively by iliac crest biopsy using the Jamshidi needle and at surgery by rib segment resection.
  • Positive cytokeratin neoplastic cells were searched by immunohistochemistry on tissue sections from the iliac crest biopsies and by flow cytometry on cell suspensions from the rib segments.
  • RESULTS: Isolated tumor cells were detected in the rib segments of ten patients.
  • CONCLUSION: Our results suggest that, if the diagnosis of bone marrow isolated tumor cells has clinical relevance, the preoperative assessment should be performed by rib segment resection or methods other than iliac crest aspirate or biopsy.
  • Further investigation is needed to determine whether isolated tumor cells have a preferential spread to chest bones other than distant bone sites.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Marrow Neoplasms / secondary. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Ilium / pathology. Lung Neoplasms / pathology. Ribs / pathology
  • [MeSH-minor] Biopsy. Cardia. Humans. Immunohistochemistry. Neoplasm Staging / methods. Stomach Neoplasms / pathology


20. Kanemoto K, Satoh H, Yamashita YT, Ishikawa H, Kamma H, Ohtsuka M, Sekizawa K: Late recurrence of small-cell lung cancer: a case report. Am J Clin Oncol; 2000 Oct;23(5):473-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was given four courses of platinum-containing chemotherapy followed by chest irradiation, and good partial response (PR) was obtained.
  • The patient did well for 4 years, until he sought treatment for a painful subcutaneous tumor.
  • Chest computed tomography scan revealed the mass extending from the tumor in lung parenchyma with osteolytic lesion of the third rib bone.
  • The patient was given two courses of the same combination chemotherapy administered as initial therapy.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Osteolysis. Ribs

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11039506.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


21. Cheng JC, Esparza SD, Knez VM, Sakamoto KM, Moore TB: Severe lactic acidosis in a 14-year-old female with metastatic undifferentiated carcinoma of unknown primary. J Pediatr Hematol Oncol; 2004 Nov;26(11):780-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of an undifferentiated carcinoma of unknown primary was made after open breast biopsy of the mass with negative immunohistochemical studies for breast malignancies.
  • Further evaluation showed extensive metastatic disease affecting the bone marrow, ribs, liver, and brain with magnetic resonance imaging evidence of carcinomatous meningitis.
  • Despite 2 months of chemotherapy and intensive supportive care, the patient died of severe lactic acidosis and disseminated intravascular coagulation after exaggerated menstrual bleeding.
  • [MeSH-minor] Adolescent. Breast Neoplasms / pathology. Disseminated Intravascular Coagulation / etiology. Fatal Outcome. Female. Hemorrhage / etiology. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology

  • Genetic Alliance. consumer health - Lactic Acidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15543020.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Pitz CC, de la Rivière AB, van Swieten HA, Duurkens VA, Lammers JW, van den Bosch JM: Surgical treatment of Pancoast tumours. Eur J Cardiothorac Surg; 2004 Jul;26(1):202-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of Pancoast tumours.
  • Due to its localisation in the apex of the lung with invasion of the lower part of the brachial plexus, first ribs, vertebrae, subclavian vessels or stellate ganglion, a superior sulcus tumour causes characteristic symptoms, like arm or shoulder pain or Horner's syndrome.
  • If rib invasion is the only feature, lysis of the rib must be evident on the chest radiograph; otherwise the tumour cannot be defined as a Pancoast tumour.
  • Shaw and Paulson introduced combined modality treatment and for many years, this combination of radiotherapy and surgery was the treatment of choice with a mean 5-year survival of approximately 30%.
  • Regarding the extent of pulmonary resection, en bloc resection of the involved ribs with a lobectomy is recommended.
  • Also the addition of other chemotherapy agents or biologic agents such as angiogenesis inhibitors or tyrosine kinase inhibitors gives a new perspective in the treatment of Pancoast tumours.
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15201002.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 54
  •  go-up   go-down


23. Doddoli C, D'Journo B, Le Pimpec-Barthes F, Dujon A, Foucault C, Thomas P, Riquet M: Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies. Ann Thorac Surg; 2005 Dec;80(6):2032-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies.
  • Multivariate analysis shows male sex and bigger tumor size as independent indicators of poor prognosis in stage IIB patients.
  • In stage IIIA patients, multivariate analysis disclosed two independent prognostic factors: the number of resected ribs and adjuvant parietal and mediastinal radiotherapy.
  • For huge tumors (larger than 6 cm), this report suggests that the role of perioperative chemotherapy needs further evaluation.
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2005 Dec;80(6):2040 [16305840.001]
  • (PMID = 16305839.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Kara Gedik G, Sari O, Altinok T, Tavli L, Kaya B, Ozcan Kara P: Askin's Tumor in an Adult: Case Report and Findings on 18F-FDG PET/CT. Case Rep Med; 2009;2009:517329

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Askin's Tumor in an Adult: Case Report and Findings on 18F-FDG PET/CT.
  • Primitive neuroectodermal tumor (PNET) of the chest wall or Askin's tumor is a rare neoplasm of chest wall.
  • It most often affects children and adolescents and is a very rare tumor in adults.
  • In this case report, we present an Askin's tumor occurred in a 73-year-old male.
  • In computed tomography, there was a lesion with dimensions of 70 x 40 x 65 mm in the superior segment of the lower lobe of the left lung.
  • Positron emission tomography/computed tomography with 18F-flourodeoxyglucose revealed a pleural-based tumor in the left lung with a maximum standardized uptake value of 4.36.
  • The patient had gone through surgery, and wedge resection of the superior segment of left lobe and partial resection of the ipsilateral ribs were performed.
  • Pathology report with immunocytochemistry was consistent with PNET and the patient received chemotherapy after that.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1293-304 [15788613.001]
  • [Cites] Pediatr Radiol. 1998 Sep;28(9):697-702 [9732497.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Mar;107(3):960-2 [8127136.001]
  • [Cites] Clin Radiol. 1991 Jan;43(1):19-23 [1847850.001]
  • [Cites] J Radiol. 1990 Mar;71(3):233-6 [2161926.001]
  • [Cites] Chest. 1990 May;97(5):1252-4 [2331925.001]
  • [Cites] Cancer. 1979 Jun;43(6):2438-51 [222426.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Oct 1;28(19):E408-12 [14520055.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):901-5 [17252575.001]
  • [Cites] Thorax. 2007 Aug;62(8):696-701 [17687098.001]
  • [Cites] Nucl Med Commun. 2006 Jan;27(1):17-24 [16340719.001]
  • (PMID = 20049330.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2797374
  •  go-up   go-down


25. Chapelier A, Fadel E, Macchiarini P, Lenot B, Le Roy Ladurie F, Cerrina J, Dartevelle P: Factors affecting long-term survival after en-bloc resection of lung cancer invading the chest wall. Eur J Cardiothorac Surg; 2000 Nov;18(5):513-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Several reports emphasize the importance of en-bloc resection as the optimal surgical treatment of lung cancer with chest wall invasion.
  • The median number of resected ribs was three (1-5).
  • Sixty-three patients received postoperative radiotherapy and 12 received chemotherapy.
  • 026) and the number of resected ribs(<2 vs. >2; P=0.03) were survival predictors in univariate analysis.
  • The role of induction chemotherapy for tumors with poor prognosis should be investigated.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy. Female. Follow-Up Studies. Hospital Mortality. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11053809.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


26. Zhu S, Li Y, Liu G, Han X, Gong L, Yao L, Lan M, Zhang W: Primary lung seminoma in a 76-year-old man: a case report. Int J Clin Exp Pathol; 2010;3(7):730-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchoscope also exhibited a neoplasm in left lung.
  • No chemotherapy or radiotherapy was given.
  • Patient was died at 140 days after the surgery mainly due to the dyscrasia and secondary seminoma in left 7th to 9th ribs.
  • CONCLUSION: Although primary seminoma of the lung is rare in old male population, the diagnosis should be taken into serious consideration in order to improve the treatment.

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Pathol Microbiol Scand. 1969;75(1):18-26 [5796079.001]
  • [Cites] J Urol. 1977 Jan;117(1):65-9 [63574.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982 Aug;396(3):247-77 [6291228.001]
  • [Cites] Acta Radiol Oncol. 1984;23(4):239-47 [6093440.001]
  • [Cites] Monaldi Arch Chest Dis. 1994 Dec;49(6):475-9 [7711696.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):63-70 [12491506.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):766-74 [12209720.001]
  • [Cites] Int J Cancer. 1996 Mar 15;65(6):723-9 [8631581.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 5;88(11):727-33 [8637026.001]
  • [Cites] Arch Pathol Lab Med. 2007 Aug;131(8):1267-80 [17683189.001]
  • [Cites] Urology. 2007 Nov;70(5):1007.e7-9 [18068470.001]
  • [Cites] Mod Pathol. 2008 Jan;21(1):54-9 [17975539.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1394-401 [11283942.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1995 Sep;86(9):1497-500 [7474641.001]
  • (PMID = 20830245.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2933394
  • [Keywords] NOTNLM ; Seminoma / immunohistochemistry / lung
  •  go-up   go-down


27. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R: Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol; 2005 Apr;184(4):1199-204
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four patients were referred for evaluation of extent of disease pretherapy and nine patients were referred for assessment of therapy response (chemotherapy, radiation therapy, bone marrow transplant).
  • In one patient, the radiographic skeletal survey showed subcentimeter lytic lesions within the ribs that were not detected on FDG PET and in the other patient, a lytic lesion detected on radiographs showed only mildly increased FDG uptake that was not identified prospectively.
  • There was one false-positive FDG PET result in a patient who had undergone radiation therapy 3 weeks before PET.
  • FDG PET was helpful in differentiating between posttherapeutic changes and residual/recurrent tumor and in assessing response to therapy.
  • FDG PET is useful in assessing extent of disease at time of initial diagnosis, contributing to staging that is more accurate.
  • FDG PET is also useful for evaluating therapy response.
  • [MeSH-major] Fluorodeoxyglucose F18. Multiple Myeloma / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788594.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


28. Fischer S, Darling G, Pierre AF, Sun A, Leighl N, Waddell TK, Keshavjee S, de Perrot M: Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet. Eur J Cardiothorac Surg; 2008 Jun;33(6):1129-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet.
  • OBJECTIVE: The role of induction therapy for non-small cell lung cancer (NSCLC) invading the thoracic inlet is unclear.
  • RESULTS: All patients underwent chest wall resection (1-5 ribs, mean 3) with resection of the first rib through an anterior (n=15), a posterior (n=18), or a combined approach (n=11).
  • On pathologic examination, 13 patients (30%) showed complete response (pCR) to induction therapy, and 15 (34%) showed minimal microscopic residual disease (90-99% tumor necrosis).
  • Sixteen patients (36%) developed recurrence, which was local in five cases and distant in 11 patients.
  • CONCLUSIONS: Resection of NSCLC invading the thoracic inlet can be performed safely after induction chemoradiation therapy.
  • The response rate after induction therapy is a strong predictor of survival.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Neoadjuvant Therapy / methods. Thorax / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy / methods. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407511.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Seemann MD: Diagnostic value of PET/CT for predicting of neoadjuvant chemotherapy response. Eur J Med Res; 2007 Feb 26;12(2):90-1
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of PET/CT for predicting of neoadjuvant chemotherapy response.
  • [MeSH-major] Breast Neoplasms / drug therapy. Drug Monitoring / methods. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Cyclophosphamide / therapeutic use. Epirubicin / therapeutic use. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymph Nodes / pathology. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Prognosis. Ribs / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369123.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down






Advertisement